The DOI matches its Crossref record; 41 of the 48 references it cites were found in a registry or an index.
The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma
Abstract
✓ This in vitro study was aimed at restitution of transforming growth factor (TGF)-β 2-mediated suppression of T-lymphocyte activation within malignant gliomas. In early-passage tumor cell cultures of two glioblastomas (HTZ-153 and HTZ-209) and one malignant astrocytoma classified as World Health Organization Grade III (HTZ-243), autologous peripheral blood mononuclear cells were activated by interleukin-lα and interleukin-2 in vitro (lymphokine-actived killer cells) and tested for cytotoxic and proliferative activity. In expression studies (Western blot and Northern hybridization) of all three tumors, TGF-β could be detected at the protein and messenger ribonucleic acid (mRNA) levels. A polyclonal anti-TGF-β neutralizing antibody did not enhance lymphocyte proliferation upon stimulation with tumor targets (3 H-thymidine incorporation) and slightly stimulated lymphocyte cytotoxicity against autologous target cells. Preincubation of target cells for 12 hours with TGF-β 2-specific phosphorothioate-anti-sense oligodeoxynucleotides (S-ODN's) did, however, enhance lymphocyte proliferation up to 2.5-fold and autologous tumor cytotoxicity up to 60%, compared to controls not treated with S-ODN's. Incubation of tumor cells with TGF-β 2-specific S-ODN's resulted in decreased TGF-β-specific immunoreactivity in cultured glioma cells, in reduced TGF-β 2 protein concentration (Western blot), and in a change in the expression pattern of TGF-β 2 mRNA's. These observations may have implications for in vivo and in vitro activation of a cellular immune response against autologous malignant glioma cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, they do not target TGF-β receptors specifically, since they equally effectively inhibit related type I receptors for several other TGF-β-related proteins, such as activin, nodal and myostatin293”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [293]
Citations
Cites
Molecular cloning: A laboratory manual
Deininger, P. L. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,684
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,218
Ashburner, M. (1989) · Cold Spring Harbor Laboratory eBooks · Cited by 6,756
Cordell, J. L., Falini, B., Erber, W. N., Ghosh, A. K., Abdulaziz, Z., MacDonald, S. M., Pulford, K. A. F., Stein, H., & Mason, D. Y. (1984) · Journal of Histochemistry & Cytochemistry · doi:10.1177/32.2.6198355 · Cited by 3,147
Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S. B., Álvarez‐Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,581
Fontana, A., Kristensen, F., Dubs, R., Gemsa, D., & Weber, E. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.6.2413 · Cited by 752
Physicochemical properties of phospborothioate oligodeoxynucleotides
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.8.3209 · Cited by 593
Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M. S., Cohen, J. S., & Broder, S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7706 · Cited by 533
Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A. (1987) · The Journal of Experimental Medicine · doi:10.1084/jem.166.4.991 · Cited by 493
Oligodeoxynucleotides as inhibitors of gene expression: a review.
Stein, C. A., & Cohen, J. S. (1988) · PubMed · Cited by 420
Cited by
Sorted by citations
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Westphal, M., Hilt, D. C., Bortey, E. B., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J. E., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,374
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Self-citation
Metadata
- Authors
- Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dörries, R., Schlingensiepen, K.-H., & Brysch, W.
- Affiliations
- University of Würzburg (DE)
- ORCID
- Behl, Christian
- Venue
- Journal of Neurosurgery
- Published
- 1993-06
- Volume
- 78
- Issue
- 6
- Pages
- 944-951
- ISSN
- 0022-3085 (ISSN-L)
- OpenAlex
- W2166484715
- Cited by
- 146
- References
- 48
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 1 · 2013: 4 · 2012: 6
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of neurosurgery (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- World Health Organization
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- transforming growth factor-beta2, high-grade glioma, glioblastoma, malignant astrocytoma, T cell activation, immunosuppression, lymphokine-activated killer cells, tumor cell killing, TGF-beta mRNA expression, autologous tumor cells, cell-mediated immunity
- MeSH terms
- Antigens, Neoplasm, Brain Neoplasms, Glioma, Humans, Immunity, Cellular, Leukocytes, Mononuclear, Phenotype, RNA, Neoplasm, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Blotting, Northern, Blotting, Western, Antigens, CD, Killer Cells, Lymphokine-Activated, Transforming Growth Factor beta, Oligonucleotides, Antisense, Immunocompromised Host
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review